



Announcement Summary

Entity name

PHARMAXIS LTD

Date of this announcement

Thursday October 12, 2023

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

| ASX +security code | Security description | Total number of +securities to be issued/transferred | Issue date |
|--------------------|----------------------|--|------------|
| PXSAAS | PERFORMANCE RIGHTS | 9,432,000 | 12/10/2023 |

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

PHARMAXIS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

75082811630

1.3 ASX issuer code

PXS

1.4 The announcement is

New announcement

1.5 Date of this announcement

12/10/2023

For personal use only



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")

For personal use only



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

PXSAAS : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

12/10/2023

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

| Name of KMP | Name of registered holder | Number of +securities |
|--------------------|---------------------------|-----------------------|
| David McGarvey | Same | 1,376,000 |
| Wolfgang Jarolimek | Same | 1,322,000 |
| Kristen Morgan | Same | 867,000 |
| Jana Baskar | Same | 1,322,000 |

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Grant Price: Nil
 2. Exercise Price: Nil
 3. Expiry: 30/6/33
 4. Each Right entitles the holder to receive one fully paid ordinary share in PXS.
 5. Vesting: 50% of will vest at 30/6/25 and 30/6/26, provided that the holder is an employee.
 6. Until 30/6/26, any shares acquired upon exercise of Rights may not be traded
 7. Any shares acquired upon exercise of Rights by Senior Executive Officers may only be traded with prior approval of the Board.
 The Performance Rights are granted pursuant to, and subject to, the terms and conditions of the Pharmaxis Performance Rights Plan - refer to the summary in the following document
<https://www.pharmaxis.com.au/assets/Documents/pdf/02021/ASX/2021-10-01-PXS-2021-AGM-Notice-of-Meeting.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Annual grant of performance rights to 22 senior managers and key staff (excluding the chief executive officer)

For personal use only



Issue details

Number of +securities

9,432,000

For personal use only



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

| ASX +security code and description | Total number of +securities on issue |
|---|---|
| PXS : ORDINARY FULLY PAID | 722,071,160 |

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|--|---|
| PXSAAT : OPTION EXPIRING 01-DEC-2027 EX \$0.11 | 5,000,000 |
| PXSAAS : PERFORMANCE RIGHTS | 35,115,945 |



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13

For personal use only